SEELOS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.291 USD | +1.89% |
|
-13.00% | -79.06% |
| Mar. 19 | Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected | MT |
| Mar. 19 | Seelos Therapeutics' ALS treatment fails in mid-stage study | RE |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 36.11 | 84.41 | 172 | 72.77 | 13.61 |
| Enterprise Value (EV) 1 | 25.85 | 78.47 | 112.2 | 77.36 | 24.85 |
| P/E ratio | -0.53 x | -3.7 x | -2.24 x | -0.98 x | -0.18 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 96,300,963 x | - | - | - | 6,179,975 x |
| EV / Revenue | 68,938,296 x | - | - | - | 11,278,477 x |
| EV / EBITDA | -0.93 x | - | - | - | - |
| EV / FCF | -2.79 x | -4.82 x | -3.7 x | -2.17 x | -4.86 x |
| FCF Yield | -35.8% | -20.8% | -27% | -46% | -20.6% |
| Price to Book | -5,174 x | 33.5 x | 3 x | -6.86 x | -0.41 x |
| Nbr of stocks (in thousands) | 898 | 1,781 | 3,516 | 3,572 | 9,795 |
| Reference price 2 | 40.20 | 47.40 | 48.90 | 20.37 | 1.390 |
| Announcement Date | 3/17/20 | 3/11/21 | 3/4/22 | 3/10/23 | 3/6/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | 0.375 | - | - | - | 2.203 |
| EBITDA 1 | -9.107 | -27.71 | - | - | - | - |
| EBIT 1 | -9.148 | -27.75 | -18.76 | -61.67 | -70.92 | -40.5 |
| Operating Margin | - | -7,399.2% | - | - | - | -1,838.36% |
| Earnings before Tax (EBT) 1 | -9.218 | -51.26 | -19.1 | -66.05 | -73.53 | -37.88 |
| Net income 1 | -9.242 | -51.26 | -19.1 | -66.05 | -73.53 | -37.88 |
| Net margin | - | -13,668% | - | - | - | -1,719.56% |
| EPS 2 | -364.3 | -75.71 | -12.80 | -21.80 | -20.74 | -7.731 |
| Free Cash Flow 1 | -4.632 | -9.264 | -16.29 | -30.29 | -35.6 | -5.115 |
| FCF margin | - | -2,470.4% | - | - | - | -232.17% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 1/22/20 | 3/17/20 | 3/11/21 | 3/4/22 | 3/10/23 | 3/6/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 0.808 | 0.336 | 0.406 | 0.653 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -10.91 | -27.37 | -14.01 | -21.24 | -17.41 | -18.26 | -8.932 | -10.95 | -12.6 | -8.011 |
| Operating Margin | - | - | - | - | - | - | -1,105.45% | -3,259.82% | -3,104.19% | -1,226.8% |
| Earnings before Tax (EBT) 1 | -10.82 | -27.26 | -14 | -21.27 | -19.6 | -18.66 | -13.43 | -29.5 | 10.5 | -5.453 |
| Net income 1 | -10.82 | -27.26 | -14 | -21.27 | -19.6 | -18.66 | -13.43 | -29.5 | 10.5 | -5.453 |
| Net margin | - | - | - | - | - | - | -1,662.25% | -8,778.57% | 2,585.71% | -835.07% |
| EPS | -3.300 | -8.400 | -3.900 | -6.000 | -5.400 | -5.100 | -3.600 | -6.600 | 2.400 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/5/21 | 3/4/22 | 5/10/22 | 8/5/22 | 11/10/22 | 3/10/23 | 5/12/23 | 8/11/23 | 11/14/23 | 3/6/24 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 4.59 | 11.2 |
| Net Cash position 1 | 3.58 | 10.3 | 5.94 | 59.8 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -4.63 | -9.26 | -16.3 | -30.3 | -35.6 | -5.11 |
| ROE (net income / shareholders' equity) | -266% | 2,175% | -1,489% | -221% | -315% | 172% |
| ROA (Net income/ Total Assets) | -109% | -307% | -82% | -76.3% | -83.4% | -180% |
| Assets 1 | 8.459 | 16.68 | 23.29 | 86.53 | 88.13 | 21.08 |
| Book Value Per Share 2 | 0.8300 | -0.0100 | 1.410 | 16.30 | -2.970 | -3.420 |
| Cash Flow per Share 2 | 1.160 | 11.40 | 8.620 | 22.40 | 4.350 | 0.3100 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 1/22/20 | 3/17/20 | 3/11/21 | 3/4/22 | 3/10/23 | 3/6/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -79.06% | 3.98M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SEEL Stock
- Financials Seelos Therapeutics, Inc.
